

ASX Announcement

12th November 2020

AGM – Chairman’s Address

AnteoTech Limited (ASX: ADO) (**‘AnteoTech’** or **‘the Company’**) is pleased to provide a copy of the Chairman’s Address to be made at the Company’s Annual General meeting being held today, set out below.

Chairman’s Address

I am sure you would all agree that 2020 has indeed been a most extraordinary year and not one we would have predicted on how the last 12 months unfolded when we gathered face to face at last year’s AGM in Sydney. The global pandemic has impacted a significant number of people, families as well as businesses and our thoughts are with all of those that this virus has impacted adversely.

For AnteoTech, our staff have been able to work continuously through the year and although COVID-19 has hampered our ability to progress our business as fast as we would have wanted in the energy space, in the Life Science sector it has presented the Company significant opportunity.

Our strategy to take the Company’s proprietary surface technology IP and focus its application in two key markets Point of Care (PoC) in Life Sciences and Anode Enhancement in Lithium-ion batteries, meant that the COVID-19 crisis presented the opportunity to accelerate our plans to move up the PoC value chain to become an assay developer.

The PoC market was growing strongly pre COVID-19, and if anything, it has been boosted in response to the pandemic. Latest forecasts by market data firm Statista¹ are predicting that the PoC world market will be valued at US\$24 B by 2026.

Part in response to the pandemic challenge, we decided to accelerate our move up the PoC value chain which bought forward Anteo achieving ISO 13485 in September allowing us to become an assay manufacturer. We also announced a successful proof of concept for a Sepis PoC test in May, and in July, the Life Science team pulled out all the stops with the announcement of successful proof of concept antibody and antigen tests for COVID-19² both standalone and in combination with Flu A/B.

Since then the focus has been on driving forward the high sensitivity² PoC antigen rapid test for the COVID-19 virus³ where we saw the highest commercial need and the best opportunity from our proof of concept tests. Excellent progress is being made, with external validation achieved in October, and we remain on track to enter clinical trials before year end. If these trials are successful, it would lead us to having a product in market subject to regulatory approval by late Q1/ early Q2 next year which is in line with the timetable announced in July. We see the market potential as very strong for a rapid COVID-19 virus antigen test which could deliver results within 15 minutes at point of testing with high sensitivity. Many experts are of the firm view that rapid testing technology delivers the quickest pathway for opening up economies, resuming broader travel and living in a world where we effectively live with another virus which becomes contained.

We are receiving strong commercial interest not only in our rapid antigen test but also for the multiplex COVID-19/Flu A/B variant and the Sepis test both of which we anticipate progressing once more resources are available.

The Energy team has also made excellent progress during the year with the focus remaining on the enhanced use of silicon in the anode of Lithium ion batteries. The latest Avicenne 'Energy⁴' outlook continues to re-enforce this strategic focus. Avicenne is forecasting the EV global Lithium ion battery market alone will exceed US\$ 100 B by 2030 at cell level. More importantly, the anode material market is forecast to grow at a 17% compound annual growth rate to 1.4 M tons by 2030, and with silicon materials, where AnteoTech is focussed, forecast to grow at a 34 % annual compound growth to 12% of the anode material market in the same time frame. The COVID-19 pandemic will also bring added impetus in the electrification of industry and transport.

A significant portion of Europe's Euro 750B pandemic stimulus package⁵ announced in July is weighted to accelerating "green" projects and technology in support of the European objective of achieving zero emissions by 2050. In recent months, China, South Korea, and Japan have all announced commitments to a timeline to zero emissions. The US election result seeing Joe Biden elected in part on a platform of climate change, proposing to take the US back into the Paris accord and a significant boost to accelerating renewable energy adoption in the US. This all points to added impetus towards electrification and increased use of batteries.

The Energy team continued to make progress on our silicon compound development and in addition we introduced AnteoX, an additive for enhancing the anode binder system for silicon compounds in November. This product is attracting very strong interest. Our collaborator network has expanded from 3 to 9 over the past 12 months and whilst COVID-19 has impacted the speed of development with our partners and is making engagement with them more challenging, we remain very much on track.

Overall, your Board is very confident that the strategy we are following is the right one and the changes in the world outlook are delivering accelerated opportunities to drive forward our core IP into commercial outcomes.

I would like to thank you our shareholders, both old and new, for your ongoing commitment to the Company. The capital raising in March raised \$ 2.15 M in what was an exceptionally volatile market at the time was well supported and allowed us to back Charlie and the Life Science team in accelerating the COVID-19 rapid test development. The options due for exercise by December 6 will bring in a further \$ 3.9 M in total before costs giving the Company a sound financial basis as we enter 2021 in what should be an exciting year for AnteoTech.

I extend my thanks to our CEO Derek Thomson, who has just passed his first anniversary with Anteo, and to all our staff who have been working at full pace and beyond to accelerate the Company's strategy in what has been at times a challenging personal and business environment given the uncertainty. Their effort has been very much appreciated.

Finally, my thanks to my Board colleagues for their focus and commitment over the past year, and if I could single out Chris Parker and Geoff Cumming who have supported Derek and the Life Science team well beyond the expectations of the role of a non-executive director in accelerating the path for our COVID-19 high sensitivity rapid antigen test. Having such technical and commercial expertise at Board level gives Anteo the ability to leverage our capability.

All at Anteo share a passion and commitment to drive this Company forward to commercial success.

This announcement has been approved by the Board.

For more information, please contact:

Derek Thomson, Chief Executive Officer, AnteoTech Ltd: +61 (0) 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

Follow AnteoTech on Twitter:



https://twitter.com/AnteoTech_ or visit www.anteotech.com

¹ The Age: "Need for Speed: rapid testing startups eye Australian opportunity" by Emma Koehn 17/10/20

² <https://www.tga.gov.au/covid-19-testing-australia-information-health-professionals#:~:text=PCR%20tests%20are%20generally%20considered,laboratory%20equipment%20and%20trained%20technicians>

³ The AnteoTech Antigen Rapid Test detects the Sars-Cov-2 active virus that causes the disease called COVID-19.

⁴ Avicenne Energy 2020

⁵ European Council announcement EUCO 10/20 21/07/2020